Liquidia FY2023 net loss $78.5M ($1.21/sh); patent victory clears path for YUTREPIA launch

Liquidia Corp

Net loss $78.5M ($1.21/sh) vs $41.0M ($0.67/sh) in FY2022; R&D spend rose 122% to $43.2M.
Cash $83.7M at Dec 31, 2023; raised $100M in Jan 2024 via equity placement and debt amendment.
Federal Circuit denied United Therapeutics' rehearing request, upholding invalidity of '793 Patent; injunction removal awaited.
YUTREPIA ready for launch in PAH and PH-ILD after Tyvaso exclusivity expires March 31, 2024 and injunction lifted.
L606 Phase 3 PH-ILD study planned by end-2024; ASCENT enrollment (60 patients) ongoing with interim data expected.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Liquidia Corp reported full year ended December 31, 2023 results: revenue $17.5 million.

Period: full year ended December 31, 2023
Revenue: $17.5 million
Result: reported results

Exact text from the filing

$25.0 million. HCRx has now invested $67.5 million in non-dilutive capital from the $100 million originally contemplated from four tranches under the RIFA. Revenue was $17.5 million for the year ended December 31, 2023, compared with $15.9 million for the year ended December 31, 2022. Revenue related primarily to the sale of Treprostinil Injection under the

View on SEC.gov

Browse all earnings releases →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-033684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.